Nanoparticles as delivery carriers for anticancer prodrugs

Expert Opinion on Drug Delivery

Volumn 9, Issue 6, 2012, Pages 657-669

  Fang, Jia You ^a,b   Al Suwayeh, Saleh A ^c  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b CHANG GUNG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

^c KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Cancer; Drug delivery; Nanoparticles; Prodrugs

Indexed keywords

AMINOLEVULINIC ACID; ANTINEOPLASTIC AGENT; CALCIUM PHOSPHATE; CAPECITABINE; CISPLATIN; COPOLYMER; CREMOPHOR; CURCUMIN; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; EZATIOSTAT; FLUOROURACIL; GEMCITABINE; IMMUNOLIPOSOME; LIPID EMULSION; MAGNETIC NANOPARTICLE; MAGNETITE NANOPARTICLE; MERCAPTOPURINE; MITOMYCIN C; NANOPARTICLE; NITRIC OXIDE; NUCLEOSIDE; PACLITAXEL; POLYACRYLIC ACID; POLYCAPROLACTONE; POLYGLACTIN; PRODRUG; SOLID LIPID NANOPARTICLE; TUBULYSIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; BIOCOMPATIBILITY; BLOOD BRAIN BARRIER; BREAST CANCER; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; COLON CANCER; CYTOTOXICITY; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DEVELOPMENT; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG POTENCY; DRUG RELEASE; DRUG SAFETY; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; DRUG TARGETING; ENDOCYTOSIS; GLIOBLASTOMA; HUMAN; HYDROLYSIS; IC 50; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA; LIPOPHILICITY; LIVER CANCER; LUNG CANCER; MAXIMUM TOLERATED DOSE; NANOEMULSION; NANOENCAPSULATION; NONHUMAN; OVARY CANCER; OVARY TUMOR; PHARMACODYNAMICS; PHARMACOKINETICS; PROSTATE CANCER; REVIEW; SKIN CANCER; SKIN STRUCTURE; STOMACH CANCER; STRATUM CORNEUM; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; DRUG DELIVERY SYSTEMS; HUMANS; LIPOSOMES; NANOPARTICLES; NEOPLASMS; PRODRUGS; SOLUBILITY;

EID: 84862064067     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2012.679927     Document Type: Review

References (85)

1. Albert A. Chemical aspects of selectivetoxicity. Nature 1958;182:421-2
2. Sloan KB, Wasdo S. Designing for topical delivery: prodrugs can make the difference. Med Res Rev 2003;23:763-93 (Pubitemid 37306013)
3. Stella VJ. Prodrugs: some thoughts and current issues. J Pharm Sci 2010;99:4755-65
4. Hsieh PW, Hung CF, Fang JY. Current prodrug design for drug discovery. Curr Pharm Des 2009;15:2236-50
5. Ettmayer P, Amidon GL, Clement B, et al. Lessons learned from marketed and investigational prodrugs. J Med Chem 2004;47:2393-404 (Pubitemid 38580074)
6. Rautio J, Kumpulainen H, Heimbach T, et al. Prodrugs: design and clinical applications. Nat Rev Drug Discov 2008;7:255-70 (Pubitemid 351324639)
7. Huttunen KM, Raunio H, Rautio J. Prodrugs - from serendipity to rational design. Pharmacol Rev 2011;63:750-71
8. Zamboni WC. Concept and clinical evaluation of carrier-mediated anticancer agents. Oncologist 2008;13:248-60 (Pubitemid 351679900)
9. Trivedi RR, Kompella UB. Nanomicellar formulations for sustained drug delivery: strategies and underlying principles. Nanomedicine 2010;5:485-505
10. Fang JY, Lee WR, Shen SC, et al. Effect of liposome encapsulation of tea catechins on their accumulation in basal cell carcinomas. J Dermatol Sci 2006;42:101-9
11. Kontermann RE. Immunoliposomes for cancer therapy. Curr Opin Mol Ther 2006;8:39-45 (Pubitemid 43230899)
12. Zhigaltsev IV, Winters G, Srinivasulu M, et al. Development of a weak-base docetaxel derivative that can be loaded into lipid nanoparticles. J Control Release 2010;144:332-40
13. Akagi T, Baba M, Akashi M. Preparation of nanoparticles by the self-organization of polymers consisting of hydrophobic and hydrophilic segments: potential applications. Polymer 2007;48:6729-47 (Pubitemid 47616262)
14. Croyand SR, Kwon GS. Polymeric micelles for drug delivery. Curr Pharm Des 2006;12:4669-84 (Pubitemid 44835136)
15. Baspinar Y, Keck CM, Borchert HH. Development of a positively charged prednicarbate nanoemulsion. Int J Pharm 2010;383:201-8
16. Wen CJ, Yen TC, Al-Suwayeh SA, et al. In vivo real-time fluorescence visualization and brain-targeting mechanisms of lipid nanocarriers with different fatty ester:oil ratios. Nanomedicine 2011;6:1545-59
17. Beduneau A, Hindre F, Clavreul A, et al. Brain targeting using novel lipid nanovectors. J Control Release 2008;126:44-9 (Pubitemid 351175685)
18. Jin Y, Xin R, Ai P, et al. Self-assembled drug delivery systems. 2. Cholesteryl derivatives of antiviral nucleotide analogues: synthesis, properties and the vesicle formation. Int J Pharm 2008;350:330-7
19. Sagnella SM, Gong X, Moghaddam MJ, et al. Nanostructured nanoparticles of self-assembled lipid pro-drugs as a route to improved chemotherapeutic agents. Nanoscale 2011;3:919-24
20. Onishi H, Machida Y. In vitro and in vivo evaluation of microparticulate drug delivery systems composed of macromolecular prodrugs. Molecules 2008;13:2136-55
21. Elsadek B, Graeser R, Esser N, et al. Development of a novel prodrug of paclitaxel that is cleaved byprostate-specific antigen: an in vitro and in vivo evaluation study. Eur J Cancer 2010;46:3434-44
22. Torchilin VP. Multifunctional nanocarriers. Adv Drug Deliv Rev 2006;58:1532-55 (Pubitemid 44822608)
23. Rooseboom M, Commandeur JNM, Vermeulen NPE. Enzyme-catalyzed activation of anticancer prodrugs. Pharmacol Rev 2004;56:53-102 (Pubitemid 38314580)
24. Kaur IP, Bhandari R, Bhandari S, et al. Potential of solid lipid nanoparticles in brain targeting. J Control Release 2008;127:97-109
25. Kabanov AV, Batrakova EV. New technologies for drug delivery across the blood brain barrier. Curr Pharm Des 2004;10:1355-63 (Pubitemid 38578372)
26. Brioschi A, Zenga F, Zara GP, et al. Solid lipid nanoparticles: could they help to improve the efficacy of pharmacological treatments for brain tumors? Neurol Res 2007;29:324-30
27. Bhalla KN, Kumar GN, Walle K, et al. Phase I and pharmacologic study of a3-hour infusion of paclitaxel followed by cisplatinum and 5-fluorouracil in patients with advanced solid tumors. Clin Cancer Res 1999;5:1723-30 (Pubitemid 29334452)
28. Forrest ML, Yanez JA, Remsberg CM, et al. Paclitaxel prodrugs with sustained release and high solubility in poly(ethylene glycol)-b-poly(epsilon- caprolactone) micelle nanocarriers: pharmacokinetic disposition, tolerability, and cytotoxicity. Pharm Res 2008;25:194-206
29. Shan L, Cui S, Du C, et al. A paclitaxel-conjugated adenovirus vector for targeted drug delivery for tumor therapy. Biomaterials 2012;33:146-62
30. Lichtman SM, Hurria A, Cirrincione CT, et al. Paclitaxel efficacy and toxicity in older women with metastatic breast cancer: combined analysis of CALGB 9342 and 9840. Ann Oncol 2012;23:632-8
31. Wang Y, Xin D, Liu K, et al. Heparin-paclitaxel conjugates as drug delivery system: synthesis, self-assembly property, drug release, and antitumor activity. Bioconjug Chem 2009;20:2214-21
32. Xin D, Wang Y, Xiang J. The use of amino acid linkers in the conjugation of paclitaxel with hyaluronic acid as drug delivery system: synthesis, self-assembled property, drug release, and in vitro efficiency. Pharm Res 2010;27:380-9
33. Li G, Liu J, Pang Y, et al. Polymeric micelles with water-insoluble drug as hydrophobic moiety for drug delivery. Biomacromolecules 2011;12:2016-26
34. Stella B, Arpicco S, Rocco F, et al. Encapsulation of gemcitabine lipophilic derivatives into polycyanoacrylate nanospheres and nanocapsules. Int J Pharm 2007;344:71-7 (Pubitemid 47464827)
35. Gong X, Moghaddam MJ, Sagnella SM, et al. Lyotropic liquid crystalline self-assembly material behavior and nanoparticulate dispersions of a phytanyl pro-drug analogue of capecitabine-A chemotherapy agent. ACS Appl Mater Interfaces 2011;3:1552-61
36. Gong X, Moghaddam MJ, Sagnella SM, et al. Lamellar crystalline self-assembly behaviour and solid lipid nanoparticles of a palmityl prodrug analogue of capecitabine-A chemotherapy agent. Colloids Surf B Biointersurf 2011;85:349-59
37. Zhang G, Liu T, Chen YH, et al. Tissue specific cytotoxicity of colon cancer cells mediated by nanoparticle-delivered suicide gene in vitro and in vivo. Clin Cancer Res 2009;15:201-7
38. Vine KL, Locke JM, Bremner JB, et al. Selective targeting of 2′-deoxy-5-fluorouridine to urokinase positive malignant cells in vitro. Bioorg Med Chem Lett 2010;20:2908-11
39. Crosasso P, Brusa P, Dosio F, et al. Antitumoral activity of liposomes and immunoliposomes containing 5-fluorouridine prodrugs. J Pharm Sci 1997;86:832-9 (Pubitemid 27297496)
40. McCarron PA, Hall M. Incorporation of novel 1-alkylcarbonyloxymethyl prodrugs of 5-fluorouracil into poly(lactide-coglycolide) nanoparticles. Int J Pharm 2008;348:115-24 (Pubitemid 350266238)
41. Immordino ML, Brusa P, Rocco F, et al. Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs. J Control Release 2004;100:331-46 (Pubitemid 39572916)
42. Couvreur P, Stella B, Reddy LH, et al. Squalenoyl nanomedicines as potential therapeutics. Nano Lett 2006;6:2544-8 (Pubitemid 46076946)
43. Bildstein L, Marsaud V, Chacun H, et al. Extracellular-protein-enhanced cellular uptake of squalenoyl gemcitabine from nanoassemblies. Soft Matter 2010;6:5570-80
44. Bildstein L, Pili B, Marsaud V, et al. Interaction of an amphiphilic squalenoyl prodrug of gemcitabine with cellular membranes. Eur J Pharm Biopharm 2011;79:612-20
45. Arias JL, Reddy LH, Couvreur P. Magnetoresponsive squalenoyl gemcitabine composite nanoparticles for cancer active targeting. Langmuir 2008;24:7512-19
46. Ansell SM, Johnstone SA, Tardi PG, et al. Modulating the therapeutic activity of nanoparticle delivered paclitaxel by manipulating the hydrophobicity of prodrug conjugates. J Med Chem 2008;51:3288-96 (Pubitemid 351821887)
47. Schluep T, Gunawan P, Ma L, et al. Polymeric tubulysin-peptide nanoparticles with potent antitumor activity. Clin Cancer Res 2009;15:181-9
48. Schluep T, Hwang J, Cheng J, et al. Preclinical efficacy of the camptothecin-polymer conjugate IT-101 in multiple cancer models. Clin Cancer Res 2006;12:1606-14
49. Taneja D, Namdeo A, Mishra PR, et al. High-entrapment liposomes for 6-mercaptopurine-A prodrug approach. Drug Dev Ind Pharm 2000;23:1315-19 (Pubitemid 32037430)
50. Kouides PA, Bennett JM. Morphology and classification of myelodysplastic syndromes. Hematol Oncol Clin North Am 1992;6:485-99
51. Raza A, Galili N, Callander N, et al. Phase 1-2a multicenter dose-escalation study of ezatiostat hydrochloride liposomes for injection (Telintra, TLK199), a novel glutathione analog prodrug in patients with myelodysplastic syndrome. J Hematol Oncol 2009;2:20
52. Bildstein L, Dubernet C, Marsaud V, et al. Transmembrane diffusion of gemcitabine by a nanoparticulate squalenoyl prodrug: an original drug delivery pathway. J Control Release 2010;147:163-70
53. Arias JL, Reddy LH, Othman M, et al. Squalene based nanocomposites: a new platform for the design of multifunctional pharmaceutical theragnostics. ACS Nano 2011;5:1513-21
54. Shubayev VI, Pisanic TR, Jin S. Magnetic nanoparticles for theragnostics. Adv Drug Deliv Rev 2009;61:467-77
55. Bildstein L, Hillaireau H, Desmaele D, et al. Freeze-drying of squalenoylated nucleoside analogue nanoparticles. Int J Pharm 2009;381:140-5
56. Caron J, Reddy LH, Lepetre-Mouelhi S, et al. Squalenoyl nucleoside monophosphate nanoassemblies: new prodrug strategy for the delivery of nucleotide analogues. Bioorg Med Chem Lett 2010;20:2761-4
57. Lundberg BB. Preparation and characterization of polymeric pH-sensitive STEALTH nanoparticles for tumor delivery of a lipophilic prodrug of paclitaxel. Int J Pharm 2011;408:208-12
58. Murad F. Discovery of some of the biological effects of nitric oxide ad its role in cell signaling. Angew Chem Int Ed 1999;38:1856-68
59. Kumar V, Hong SY, Maciag AE, et al. Stabilization of the nitric oxide (NO) prodrugs and anticancer leads, PABA/ NO and double JS-K, through incorporation into PEG-protected nanoparticles. Mol Pharm 2010;7:291-8
60. Vij N, Min T, Marasigan R, et al. Development of PEGylated PLGA nanoparticle for controlled and sustained drug delivery in cystic fibrosis. J Nanobiotechnol 2010;8:22
61. Cheon EP, Hong JH, Han HK. Enhanced cellular uptake of Ara-C via apeptidomimetic prodrug, L-valyl-ara-C in Caco-2 cells. J Pharm Pharmacol 2006;58:927-32 (Pubitemid 43967109)
62. Tokunaga Y, Iwasa T, Fujisaki J, et al. Liposomal sustained-release delivery systems for intravenous injection. IV. Antitumor activity of newly synthesized lipophilic 1-beta-D-arabinofuranosylcytosine prodrug-bearing liposomes. Chem Pharm Bull 1988;36:3574-83
63. Mori A, Kennel SJ, Huang L. Immunotargeting of liposomes containing lipophilic antitumor prodrugs. Pharm Res 1993;10:507-14 (Pubitemid 23113040)
64. Dimou A, Syrigos KN, Saif MW. Is there a role for mitomycin C in metastatic colorectal cancer? Expert Opin Invest Drugs 2010;19:723-35
65. Gabizon AA, Tzemach D, Horowitz AT, et al. Reduced toxicity and superior therapeutic activity of a mitomycin Clipid-based prodrug incorporated in Pegylated liposomes. Clin Cancer Res 2006;12:1913-20
66. Dhar S, Daniel W, Giljohann DA, et al. Polyvalent oligonucleotide gold nanoparticle conjugates as delivery vehicles for platinum(IV) warheads. J Am Chem Soc 2009;131:14652-3
67. Seferos DS, Prigodich AE, Giljohann DA, et al. Polyvalent DNA nanoparticle conjugates stabilize nucleic acids. Nano Lett 2009;9:308-11
68. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300
69. Dhar S, Gu FX, Langer R, et al. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt (IV) prodrug-PLGA-PEG nanoparticles. Proc Natl Acad Sci 2008;105:17356-61
70. Dhar S, Kolishetti N, Lippard SJ, et al. Targeted delivery of a cisplatin prodrug for safer and more effective cancer therapy in vivo. Proc Natl Acad Sci 2011;108:1850-5
71. Kholishetti N, Dhar S, Valencia PM, et al. Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy. Proc Natl Acad Sci 2010;107:17939-44
72. Vaughan EE, Geiger RC, Miller AM, et al. Microtubule acetylation through HDAC6 inhibition results in increased transfection efficiency. Mol Ther 2008;16:1841-7
73. Ishii Y, Hattori Y, Yamada T, et al. Histone deacetylase inhibitor prodrugs in nanoparticle vector enhanced gene expression in human cancer cells. Eur JMed Chem 2009;44:4603-10
74. Versluis AJ, Rump ET, Rensen PCN, et al. Stable incorporation of a lipophilic daunorubicin prodrug into apolipoprotein E-exposing liposomes induces uptake of prodrug via low-density lipoprotein receptor in vivo. J Pharmacol Exp Ther 1999;289:1-7 (Pubitemid 29156005)
75. Weiss RB. The anthracyclines: will we ever find a better doxorubicin? Semin Oncol 1992;19:670-86 (Pubitemid 23004844)
76. Yu BT, Sun X, Zhang ZR. Enhanced liver targeting by synthesis of N1-stearyl-5-Fu and incorporation into solid lipid nanoparticles. Arch Pharm Res 2003;26:1096-101
77. Holland EC. Glioblastoma multiform: the terminator. Proc Natl Acad Sci 2000;97:6242-4
78. Nikanjam M, Gibbs AR, Hunt CA, et al. Synthetic nano-LDL with paclitaxel oleate as a targeted drug delivery vehicle for glioblastoma multiforme. J Control Release 2007;124:163-71 (Pubitemid 350101886)
79. Rensen PC, de Vrueh RL, Kuiper J, et al. Recombinant lipoproteins: lipoprotein-like lipid particles for drug targeting. Adv Drug Deliv Rev 2001;47:251-76 (Pubitemid 32324117)
80. Tang H, Murphy CJ, Zhang B, et al. Amphiphilic curcumin conjugate-forming nanoparticles as anticancer prodrug and drug carriers: in vitro and in vivo effects. Nanomedicine 2010;5:855-65
81. Liu T, Zhang G, Chen YH, et al. Tissue specific expression of suicide genes delivered by nanoparticles inhibits gastric carcinoma growth. Cancer Biol Ther 2006;5:1683-90
82. Christiansen K, Bjerring P, Troilius A. 5-ALA for photodynamic photo-rejuvenation-Optimization of treatment regime based on normal-skin fluorescence measurements. Lasers Surg Med 2007;39:302-10 (Pubitemid 46717529)
83. Zhang LW, Al-Suwayeh SA, Hung CF, et al. Oil components modulate the skin delivery of 5-aminolevulinic acid and its ester prodrug from oil-in-water and water-in-oil nanoemulsions. Int J Nanomed 2011;6:693-704
84. Yang RSH, Chang LW, Yang CS, et al. Pharmacokinetics and physiologically-based pharmacokinetic modeling of nanoparticles. J Nanosci Nanotechnol 2010;10:8482-90
85. Oberdorster G, Stone V, Donaldson K. Toxicology of nanoparticles: a historical perspective. Nanotoxicology 2007;1:2-25 (Pubitemid 46570244)